Predictive factors for response and progression after treatment with rituximab in previously untreated patients with Waldenstrom's macroglobulinemia (WM).

被引：0
|
作者：
Anagnostopoulos, A
Treon, SP
Zervas, K
Branagan, A
Gika, D
Zomas, A
Kyrtsonis, MC
Vassou, A
Anagnostopoulos, N
Pangalis, G
Dimopoulos, MA
机构：
[1] Greek Myeloma Study Grp, Dept Clin Therapeut, Athens, Greece
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3485
引用
收藏
页码：973A / 973A
页数：1
相关论文
共 50 条
  • [21] Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia
    Ghobrial, Irene M.
    Padmanabhan, Swaminathan
    Badros, Ashraf Z.
    Leduc, Renee
    Rourke, Meghan
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul
    Treon, Steven
    Matous, Jeffrey
    BLOOD, 2009, 114 (22) : 1444 - 1444
  • [22] Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia
    Treon, Steven P.
    Meid, Kirsten
    Gustine, Joshua
    Patterson, Christopher J.
    Matous, Jeffrey V.
    Ghobrial, Irene M.
    Castillo, Jorge J.
    BLOOD, 2015, 126 (23)
  • [23] Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM)
    Chen, CI
    White, D
    Kouroukis, CT
    Stewart, AK
    Howson-Jan, K
    Larratt, L
    Powers, J
    Eisenhauer, E
    BLOOD, 2004, 104 (11) : 896A - 896A
  • [24] Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM):: Results in 21 patients (pts).
    Vargaftig, Jacques
    Pegourie-Bandelier, Brigitte
    Mahe, Beatrice
    Le Gouill, Steven
    Brottier-Mancini, Elisabeth
    Delarue, Richard
    Buzyn, Agnes
    Raphael, Martine
    Choquet, Sylvain
    Leblond, Veronique
    BLOOD, 2006, 108 (11) : 264B - 264B
  • [25] 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia
    Weber, DM
    Dimopoulos, MA
    Delasalle, K
    Rankin, K
    Gavino, M
    Alexanian, R
    SEMINARS IN ONCOLOGY, 2003, 30 (02) : 243 - 247
  • [26] The Natural History of Asymptomatic (Smoldering) Waldenstrom Macroglobulinemia (WM): Factors Predicting Progression to Symptomatic WM and Transformation
    Kaldas, David
    Thapa, Shrin
    Modukuri, Shrikar
    Shain, Ken
    Blue, Brandon
    Alsina, Melissa
    Baz, Rachid
    Grajales-Cruz, Ariel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S506 - S506
  • [27] Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenstrom's macroglobulinemia
    Herth, Isabelle
    Hensel, Manfred
    Rieger, Michael
    Horstmann, Kristin
    Hiddemann, Wolfgang
    Dreyling, Martin
    Koniczek, Silvia
    Witzens-Harig, Mathias
    Ho, Anthony D.
    LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 97 - 102
  • [28] Abrupt IgM rise following treatment with rituximab in patients with Waldenstrom's macroglobulinemia
    Donnelly, GB
    Bober-Sorcinelli, K
    Jacobson, R
    Portlock, CS
    BLOOD, 2001, 98 (11) : 240B - 241B
  • [29] Pentostatin, cyclophosphamide and rituximab is safe and effective treatment for patients with Waldenstrom's Macroglobulinemia
    Herth, I
    Hensel, M.
    Rieger, M.
    Horstmann, K.
    Witzens-Harig, M.
    Ho, A. D.
    ONKOLOGIE, 2013, 36 : 32 - 32
  • [30] Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia
    Castillo, Jorge J.
    Gustine, Joshua N.
    Keezer, Andrew
    Meid, Kirsten
    Flynn, Catherine A.
    Dubeau, Toni E.
    Chan, Gloria
    Chen, Jiaji
    Demos, Maria G.
    Guerrera, Maria L.
    Jimenez, Cristina
    Kofides, Amanda
    Liu, Xia
    Munshi, Manit
    Tsakmaklis, Nicholas
    Patterson, Christopher J.
    Xu, Lian
    Yang, Guang
    Hunter, Zachary R.
    Treon, Steven P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (04) : 372 - 378
12345